Английская Википедия:Bifeprunox
Шаблон:Short description Шаблон:Drugbox Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism.[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.[2]
In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.[3]An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]
Pharmacodynamics
Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.
See also
References
Шаблон:Antipsychotics Шаблон:Dopaminergics Шаблон:Serotonergics Шаблон:Piperazines
- ↑ Шаблон:Cite journal
- ↑ Шаблон:Cite web
- ↑ Шаблон:Cite journal
- ↑ Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
- ↑ Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Шаблон:Webarchive Lundbeck Press Release.
